3 Stocks Pushing The Health Care Sector Lower

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading up 15 points (0.1%) at 12,980 as of Tuesday, Dec. 4, 2012, 11:49 AM ET. The NYSE advances/declines ratio sits at 1,319 issues advancing vs. 1,553 declining with 162 unchanged.

The Health Care sector currently sits down 0.3% versus the S&P 500, which is down 0.1%. Top gainers within the sector include Edwards Life ( EW), up 4.5%, Shire ( SHPG), up 2.7%, Valeant Pharmaceuticals International ( VRX), up 1.1%, Abbott Laboratories ( ABT), up 0.8% and GlaxoSmithKline ( GSK), up 0.8%.

TheStreet Ratings group would like to highlight 3 stocks pushing the sector lower today:

3. BioMarin Pharmaceuticals ( BMRN) is one of the companies pushing the Health Care sector lower today. As of noon trading, BioMarin Pharmaceuticals is down $0.88 (-1.8%) to $47.81 on light volume Thus far, 155,248 shares of BioMarin Pharmaceuticals exchanged hands as compared to its average daily volume of 1.7 million shares. The stock has ranged in price between $47.72-$48.66 after having opened the day at $48.58 as compared to the previous trading day's close of $48.69.

BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and rest of the world. BioMarin Pharmaceuticals has a market cap of $6.0 billion and is part of the drugs industry. Shares are up 41.6% year to date as of the close of trading on Monday. Currently there are 11 analysts that rate BioMarin Pharmaceuticals a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates BioMarin Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity and feeble growth in the company's earnings per share. Get the full BioMarin Pharmaceuticals Ratings Report now.

EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass

If you liked this article you might like

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst

Trump's FDA: A Friendlier Biotech Sheriff

Arena Pharma's Stock Could Still Double Even After Tuesday's Epic Run

Why I Hate the FAANGs (but Like Banks and Biotech) for 2017's Second Half

3 Fearless Predictions for the Second Half